Get started
PFIZER INCPFIZER INCPFIZER INC

PFIZER INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFECL trade ideas

$PFE | Allocation/Buy Trade | Market Exec |Technical Confluences: - Price is in Oversold Conditions in D1 timeframe - Price action bouncing off 150% Fibo Extension - Price is trying to go back above the Interest Zone to give some bullish momentum to the stock Fundamental Confluences: -Regardless how bad the negative rumours are ongoing about the side-effects from Pfizer; they are still considered a strong market leader in the Pharma industry - They had a good response on a testing of their recent respiratory drug - Value? ---- Health sector in your Portfolio will never be wrong with the global aging population. I am putting this trade on as either into my Long-Term Portfolio or Swing trade for $PFE. Depending on how market develops, I may decide to hold this bag and allocate more into it at the 178% Fibo Extension levels or cut my Buy position as shown. -----
NYSE:PFELong
by weekendanalyst
Is Pfizer Trying to Turn?Pfizer has struggled for years, but some traders may see signs of a turn. The first pattern on today’s chart is the pair of positive moves after stronger-than-expected earnings reports. Those may reflect improving fundamentals for the drugmaker. Second, the 50-day simple moving average (SMA) had a “golden cross” above the 200-day SMA last month. Has the longer-term trend improved? Next, PFE made a lower low on Tuesday versus Monday and a higher high. That “outside day” may be viewed as a potentially bullish reversal pattern. Finally, stochastics turned up after hitting an oversold condition. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NYSE:PFE
by TradeStation
1
PFE is it completed the Accumulation and Going to Fly ?! It is the first time to break out the wide range since DEC 2023 Now We are in Phase E ( Trading outside the Range) - Wyckoff Method Supply showing Effort with no result Demand has Increased Also there is upcoming earning so, Is the accumulation phase has completed and we are going to 🚀 ?! TP 01 : 34.71 TP 02: 37.17 SL: 29.30 I am Just sharing insights and market trends for learning and growing every day and it is not financial advice.
NYSE:PFELong
by FSelim55
PERFECT TIME TO BUY. $PFE to $32 before Next Earning The falling wedge is a bullish price formation that tells a tale of the stock where bulls are gearing up for a new rally. + NYSE:PFE is trading below my estimate of fair value ($68.47). OVERSOLD! + Their Earning is expected to return to the $9-10 billion range (Pre-Covid). The current earning is 2.13 billion. + Paxlovid, Prevnar, Elliquis, Ibrance, Xeljanz, Enbrel and Zithromax/Zmax continue to be the most effecitive medications. + Pfizer, a company that pays dividends, currently has a yield of 6.21%. I have faith in my chart analysis, however, even if there are inconsistencies, dividends will continue to be distributed, which solidifies its attractiveness as a long-term investment opportunity. Risk-Free & East Gain
NYSE:PFELong
by sej4974
PFE - our Long Call materializesOur recent recommended top pick from Healthcare sector: PFE: released better than expected financial results; raised full year guidance; The company’s earnings per share (EPS) in the second quarter stood at $0.60, surpassing the consensus estimate of $0.46. Revenue came in at $13.3 billion, also above the projected $13.03 billion. Pfizer reported adjusted research and development expenses of $2.67 billion for the period, compared to the estimated $2.83 billion. Looking forward, the pharmaceutical giant now projects FY2024 EPS of $2.45 to $2.65, up from the previous guidance of $2.15 to $2.35, and above the consensus estimate of $2.38.
NYSE:PFELong
by IrinaTK
price levels to trade PFE after its earningCertainly! **Pfizer** has been actively advancing its gene therapy pipeline, particularly in the field of hemophilia. Here are some key developments: 1. **Giroctocogene fitelparvovec**: - Pfizer announced positive topline results from the **Phase 3 AFFINE study** evaluating giroctocogene fitelparvovec. This investigational gene therapy targets **hemophilia A** in adults with moderately severe to severe forms of the condition. - Key findings: - Achieved its primary objective of **non-inferiority** and **superiority** compared to routine Factor VIII (FVIII) replacement prophylaxis treatment. - Demonstrated a statistically significant reduction in mean total annualized bleeding rate (ABR) compared to the pre-infusion period. - Most participants maintained FVIII activity >5% at 15 months post-infusion. - Generally well-tolerated, with no impact on efficacy and safety results¹. - Notably, Pfizer also received FDA approval for **Beqvez**, a gene therapy for **hemophilia B**. - Additionally, regulatory submissions for **marstacimab** as a potential treatment for both hemophilia A and B are underway in the U.S. and Europe². 2. **Other Gene Therapy Programs**: - Pfizer currently has three Phase 3 programs investigating gene therapy in populations with high unmet needs: - **Hemophilia B** - **Hemophilia A** - **Duchenne muscular dystrophy**³. Pfizer's commitment to advancing gene therapies holds great promise for patients worldwide. 🌟🧬⁴⁵ 🚀 Source: Conversation with Copilot, 7/30/2024 (1) Pfizer Announces Positive Topline Results From Phase 3 Study of .... www.pfizer.com (2) Pfizer Hemophilia Gene Therapy Meets Phase 3 Goals, But Its Success .... medcitynews.com (3) Pfizer Announces Positive Top-Line Results from Phase 3 Study of .... www.pfizer.com (4) Pfizer Pipeline. cdn.pfizer.com (5) New Drug Development Pipeline: Pfizer's Medicine, Vaccine Discovery .... www.pfizer.com
NYSE:PFELong
by KhanhC.Hoang
Pfizer (PFE) AnalysisOverview:** Pfizer Inc. (PFE) has been in a prolonged downtrend but is showing signs of potential recovery. The recent chart indicates a bounce from the lows, with key technical indicators suggesting a possible reversal. **Technical Analysis:** 1. **Fibonacci Retracement Levels**: - The chart shows Fibonacci retracement levels drawn from the recent high to the low. The stock has rebounded from the lower levels and is currently testing the 23.6% retracement level around $29.50. A sustained break above this level could target the next resistance levels at $32 and $35. 2. **Moving Averages**: - The stock has moved above the short-term moving averages (indicated by the green and blue lines), which suggests bullish momentum. If it can maintain above these levels, it could attract more buying interest. 3. **MACD and RSI**: - The MACD indicator shows a bullish crossover, and the histogram has turned positive, indicating increasing bullish momentum. - The RSI is rising from oversold territory, currently at 87.03, which suggests strong buying pressure but also warrants caution as it nears overbought levels. **Fundamental Perspective:** - **Recent Developments**: Pfizer's ongoing developments in its drug pipeline, including advancements in COVID-19 treatments and vaccines, continue to provide long-term growth potential. Investors should keep an eye on upcoming earnings reports and updates on key products. - **Valuation** The current price level may represent a value opportunity given Pfizer's strong balance sheet and consistent dividend payments. The company has a history of generating significant free cash flow, which supports its ability to invest in new research and return capital to shareholders. **Conclusion:** Pfizer appears to be at a crucial juncture, with technical indicators suggesting a potential trend reversal. Investors should monitor the $29.50 level for a possible breakout and consider the broader market conditions and Pfizer’s upcoming announcements for further confirmation of the bullish trend. **Risk Management:** - Set stop-loss orders below recent lows to manage downside risk. - Consider scaling into the position to mitigate the impact of volatility. **Disclaimer**: This analysis is for informational purposes only and should not be considered as financial advice. Dr SAUD
NYSE:PFELong
by DrSaud1
Pfizer: This sell off is nowhere near finished Pfizer has been getting pushed like crazy on CNBC by fund managers like Josh Brown as a good buy and after looking at the charts above its very easy to see why. Wallstreet pricks like Brown are trying to offload their last remaining shares on unsuspecting retail buyers. As you can see in the first chart on the daily timeframe, Pfizer is below the 200 and tried 3 different times to get above it and failed. In the second chart on the monthly timeframe, Pfizer is now below the 200 on the Monthly and is now consolidating, the last time this happened was back in 2009 and after consolidating below the 200 for 3 months, it tanked 50% for 15 months in a row, from $22.50 down to just under $13 a share. Pfizer will not be a buy for a long long time NYSE:PFE
NYSE:PFEShort
by bradc1984
3